CL2021002401A1 - Extractos bacterianos estables como fármacos - Google Patents

Extractos bacterianos estables como fármacos

Info

Publication number
CL2021002401A1
CL2021002401A1 CL2021002401A CL2021002401A CL2021002401A1 CL 2021002401 A1 CL2021002401 A1 CL 2021002401A1 CL 2021002401 A CL2021002401 A CL 2021002401A CL 2021002401 A CL2021002401 A CL 2021002401A CL 2021002401 A1 CL2021002401 A1 CL 2021002401A1
Authority
CL
Chile
Prior art keywords
novel
bacterial extracts
drug
stable bacterial
stable
Prior art date
Application number
CL2021002401A
Other languages
English (en)
Inventor
Jacques Bauer
Christian Pasquali
Original Assignee
Om Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Om Pharma Sa filed Critical Om Pharma Sa
Publication of CL2021002401A1 publication Critical patent/CL2021002401A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/08—Reducing the nucleic acid content
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se relaciona con preparaciones de extractos bacterianos estables novedosas que tienen estabilidad sustancialmente incrementada con el tiempo, métodos novedosos de preparación de las mismas, formulaciones farmacéuticas basadas en los extractos bacterianos estabilizados novedosos, así como rutas novedosas de administración y dispositivos de liberación para tratar y/o prevención de trastornos inmunológicos agudos y crónicos resultantes de infecciones y/o inflamación y/o neoplasmas y/o disbiosis.
CL2021002401A 2019-03-14 2021-09-14 Extractos bacterianos estables como fármacos CL2021002401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19162912 2019-03-14

Publications (1)

Publication Number Publication Date
CL2021002401A1 true CL2021002401A1 (es) 2022-04-08

Family

ID=65991511

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002401A CL2021002401A1 (es) 2019-03-14 2021-09-14 Extractos bacterianos estables como fármacos

Country Status (19)

Country Link
US (2) US11801271B2 (es)
EP (2) EP3937957A1 (es)
JP (1) JP2022525177A (es)
KR (1) KR20210141546A (es)
CN (1) CN113840615A (es)
AU (1) AU2020235261A1 (es)
BR (1) BR112021018006A2 (es)
CA (1) CA3132564A1 (es)
CL (1) CL2021002401A1 (es)
CO (1) CO2021013677A2 (es)
CR (1) CR20210515A (es)
CU (1) CU20210077A7 (es)
IL (1) IL286215A (es)
MA (1) MA55291A (es)
MX (1) MX2021010912A (es)
PE (1) PE20212261A1 (es)
SG (1) SG11202109937UA (es)
WO (1) WO2020182970A1 (es)
ZA (1) ZA202106914B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113613665A (zh) * 2019-03-14 2021-11-05 Om药物公司 治疗和/或预防哮喘、哮喘恶化、过敏性哮喘和/或与呼吸系统病症相关的微生物群相关的病症的方法
TW202304485A (zh) * 2021-04-12 2023-02-01 香港中文大學 用於增強免疫力的方法和組合物
WO2022233441A1 (en) * 2021-05-07 2022-11-10 Symrise Ag Novel bacterial ferment of lactobacillus species
EP4134426A1 (en) * 2021-08-13 2023-02-15 Symrise AG Novel bacterial ferment of lactobacillus species
WO2023120547A1 (ja) * 2021-12-22 2023-06-29 株式会社明治 二次性感染症の予防又は発症リスクを低減するための組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8007911A (pt) 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
US4811731A (en) 1985-07-30 1989-03-14 Glaxo Group Limited Devices for administering medicaments to patients
SK280967B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Inhalačný prístroj
CH685498A5 (fr) 1992-02-14 1995-07-31 Om Lab Sa Extrait de macromolécules bactériennes, procédé pour sa préparation et composition pharmaceutique contenant cet extrait.
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
US7171965B2 (en) 2000-02-01 2007-02-06 Valois S.A.S. Breath actuated dry powder inhaler and tape dose strip
US6994083B2 (en) 2001-12-21 2006-02-07 Trudell Medical International Nebulizer apparatus and method
WO2006060282A2 (en) * 2004-11-30 2006-06-08 Merial Limited Mixing devices for chemical lysis of cells
US20080170996A1 (en) * 2006-07-28 2008-07-17 The Board Of Regents Of The University Of Texas System Compositions and Methods for Stimulation of Lung Innate Immunity
DK2114421T3 (en) 2007-03-05 2018-04-23 Om Pharma BACTERIA EXTRACTS FOR RESPIRATORY DISORDERS AND PROCEDURES FOR PREPARING THEREOF
JP6041458B2 (ja) 2007-03-05 2016-12-07 オーエム ファーマＯｍ Ｐｈａｒｍａ 消化管又は尿管の障害のための細菌抽出物及びその製造方法
GB0818453D0 (en) * 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
ES2356883B1 (es) 2008-07-24 2012-02-22 Bcn Peptides, S.A. Composición para el tratamiento del dolor y/o la inflamación.
RU2500412C2 (ru) 2008-09-04 2013-12-10 Ом Фарма ИММУНОМОДУЛИРУЮЩИЕ ЭКСТРАКТЫ ИЗ БАКТЕРИЙ Lactobacillus И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
RU2425691C1 (ru) 2010-07-15 2011-08-10 ВАКЕ спол с.р.о. Аэрозольный препарат на основе апротинина для лечения вирусных респираторных инфекций
CN101979541A (zh) * 2010-10-28 2011-02-23 徐堤 一种快速共价闭合环状dna纯化试剂盒
CN110290799A (zh) * 2016-12-13 2019-09-27 防御素治疗学公司 用于治疗肺部炎性病症的方法

Also Published As

Publication number Publication date
US20230346855A1 (en) 2023-11-02
US20210401902A1 (en) 2021-12-30
CR20210515A (es) 2022-03-28
KR20210141546A (ko) 2021-11-23
MX2021010912A (es) 2021-10-01
CO2021013677A2 (es) 2021-10-20
EP3937957A1 (en) 2022-01-19
SG11202109937UA (en) 2021-10-28
CA3132564A1 (en) 2020-09-17
CN113840615A (zh) 2021-12-24
CU20210077A7 (es) 2022-04-07
PE20212261A1 (es) 2021-11-29
WO2020182970A1 (en) 2020-09-17
ZA202106914B (en) 2023-10-25
BR112021018006A2 (pt) 2021-11-16
EP4234026A2 (en) 2023-08-30
IL286215A (en) 2021-10-31
US11801271B2 (en) 2023-10-31
MA55291A (fr) 2022-01-19
JP2022525177A (ja) 2022-05-11
AU2020235261A1 (en) 2021-09-16
EP4234026A3 (en) 2024-07-03

Similar Documents

Publication Publication Date Title
CL2021002401A1 (es) Extractos bacterianos estables como fármacos
CO2018013654A2 (es) Composiciones nasales de cannabidiol
MX2019000427A (es) Formas de dosificacion oral de cannabinoide de alta concentracion.
CL2017002939A1 (es) Composiciones farmacéuticas tópicas
BR112017008301A2 (pt) extratos de cannabis e métodos de sua preparação e uso
CL2019003309A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2019002745A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2019003635A1 (es) Composiciones y tratamientos para el trastorno del sueño.
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112019001852A2 (pt) composição de cannabis
CL2019002744A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
BR112018073663A2 (pt) moduladores de receptores nmda spiro-lactâmicos e seus usos
CL2020000747A1 (es) Formulaciones de niraparib.
CL2019003294A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CO2019000643A2 (es) Formulaciones gastrorretentivas orales y usos de las mismas
CL2019001658A1 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
CY1117881T1 (el) Στερεες φαρμακευτικες συνθεσεις που περιλαμβανουν παραγωγα βιοπτερινης και χρησεις αυτων των συνθεσεων
CO2020005485A2 (es) Administración oral de análogos del péptido glp-1
EA201892842A1 (ru) Фармацевтические композиции, включающие сафинамид
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
EA202090666A1 (ru) Применение содержащей бензоат композиции для лечения глициновой энцефалопатии
BR112018012616A2 (pt) formulação galênica que compreende um fármaco tópico
CL2020002398A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")
AR114282A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida (“tcd”)